<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36913029</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Adaptation and validation of the Bulgarian version of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL).</ArticleTitle><Pagination><StartPage>1811</StartPage><EndPage>1817</EndPage><MedlinePgn>1811-1817</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06523-w</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Systemic lupus erythematosus (SLE) is a heterogeneous disease with multiple clinical manifestations, which causes a significant deterioration in the quality of life (QoL). The Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) is a lupus-specific measure used to determine the burden of the disease and it applies the need-based model of QoL. Our aim was to produce the first successfully validated foreign language version of the questionnaire.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The development of the Bulgarian version involved three stages: translation, field testing and psychometric evaluation. Translation was conducted by an expert linguist working with a developer of the original L-QoL, followed by interviews with monolingual lay individuals. Face and content validity of the translation were assessed by cognitive debriefing interviews with Bulgarian SLE patients. Finally, the L-QoL was validated by administering the questionnaire to a random sample of SLE patients on two occasions, 2 weeks apart to evaluate its reliability and validity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the validation survey, the new Bulgarian version demonstrated high internal consistency (the Cronbach's alpha coefficient was 0.92), and test-retest reliability (0.97). Additionally, scores on the L-QoL were correlated with those on the SF-36 sections to determine convergent validity and the strongest correlation was observed between L-QoL scores and the social functioning section of the SF-36. Known group validity was established by testing the ability of the Bulgarian L-QoL to distinguish between subgroups of patients from the study pool.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The demonstrated excellent psychometric properties ensure that the Bulgarian L-QoL accurately captures the impact of SLE on the quality of life. Key points &#x2022; The Bulgarian version of the L-QoL is a valid and reliable measure of QoL in lupus patients. &#x2022; The Bulgarian version of the L-QoL can be used as an outcome measure in research, clinical trials and routine clinical practice.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pencheva</LastName><ForeName>Daliya Tsvetanova</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0002-6590-7100</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, Medical University of Sofia, Sofia, Bulgaria. dpencheva@medfac.mu-sofia.bg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, University Clinical Hospital 'St. Ivan Rilski', Sofia, Bulgaria. dpencheva@medfac.mu-sofia.bg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coffey</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8058-0337</Identifier><AffiliationInfo><Affiliation>Galen Research Ltd, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0003-4238-8333</Identifier><AffiliationInfo><Affiliation>Galen Research Ltd, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health Sciences, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monov</LastName><ForeName>Simeon Valentinov</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0001-8074-3768</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, University Clinical Hospital 'St. Ivan Rilski', Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002031" MajorTopicYN="N" Type="Geographic">Bulgaria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptation</Keyword><Keyword MajorTopicYN="N">L-QoL</Keyword><Keyword MajorTopicYN="N">Patient-reported outcome measures (PROMs)</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Validation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>13</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36913029</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06523-w</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06523-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, Ruiz-Irastorza G, Hughes G (2016) Systemic lupus erythematosus. Nat Rev Dis Primers 2:16039. https://doi.org/10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon GE, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, G&#xfc;l A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69(1):61&#x2013;64. https://doi.org/10.1136/ard.2008.102533</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.102533</ArticleId><ArticleId IdType="pubmed">19155235</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force Lupus. Sci Med 8:e000538. https://doi.org/10.1136/lupus-2021-000538</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75(9):1615&#x2013;1621. https://doi.org/10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69(7):1269&#x2013;1274. https://doi.org/10.1136/ard.2009.117200</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.117200</ArticleId><ArticleId IdType="pubmed">19892750</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P (2000) Endpoints: consensus recommendations from OMERACT IV. Lupus 9(5):322&#x2013;327. https://doi.org/10.1191/096120300678828424</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300678828424</ArticleId><ArticleId IdType="pubmed">10878722</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra S&#xe1;nchez AR, Voskuyl AE, van Vollenhoven RF (2022) Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 18(3):146&#x2013;157. https://doi.org/10.1038/s41584-021-00739-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00739-3</ArticleId><ArticleId IdType="pubmed">35039665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Clowse MEB, Criscione-Schreiber LG, Rogers JL (2019) A novel system to categorize the symptoms of systemic lupus erythematosus arthritis. Care Res 71(6):735&#x2013;741. https://doi.org/10.1002/acr.23794</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE Jr (2000) SF-36 health survey update. Spine 25:3130&#x2013;3139. https://doi.org/10.1097/00007632-200012150-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007632-200012150-00008</ArticleId><ArticleId IdType="pubmed">11124729</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, Empson B, Griffiths B, Jayne D, Khamashta M, Lightstone L, Norton P, Norton Y, Schreiber K, Isenberg D, British Society for Rheumatology Standards, Audit and Guidelines Working Group (2018) The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57(1):e1&#x2013;e45. https://doi.org/10.1093/rheumatology/kex286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex286</ArticleId><ArticleId IdType="pubmed">29029350</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, Peers K, Isenberg D, Ferenkeh-Koroma A, Griffiths B, Akil M, Maddison P, Teh LS (2007) Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 57(6):972&#x2013;979. https://doi.org/10.1002/art.22881</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22881</ArticleId><ArticleId IdType="pubmed">17665467</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, Cheng YK, Chng HH, Badsha H, Law WG, Lau TC, Chew LC, Ho HJ, Pong LY, Hoi LS, Sangeetha N, Chan SP, Howe HS (2005) Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 44(10):1267&#x2013;1276. https://doi.org/10.1093/rheumatology/keh605</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh605</ArticleId><ArticleId IdType="pubmed">15797980</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, Rodby RA, Fogg L, Sequeira W, Utset TO, Cash TF, Moldovan I, Katsaros E, Nicassio P, Ishimori ML, Kosinsky M, Merrill JT, Weisman MH, Wallace DJ (2012) Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 42(1):56&#x2013;65. https://doi.org/10.1016/j.semarthrit.2011.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.12.005</ArticleId><ArticleId IdType="pubmed">22480408</ArticleId></ArticleIdList></Reference><Reference><Citation>Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ (2009) The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 68(2):196&#x2013;200. https://doi.org/10.1136/ard.2007.086009</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.086009</ArticleId><ArticleId IdType="pubmed">18385276</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SM, McKenna SP (1992) The QLDS: a scale for the measurement of quality of life in depression. Health Policy 22:307&#x2013;319. https://doi.org/10.1016/0168-8510(92)90004-u</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8510(92)90004-u</ArticleId><ArticleId IdType="pubmed">10122730</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley D, McKenna SP, de Jong Z, van der Heijde D (1997) Quality of life in rheumatoid arthritis. Br J Rheumatol 1997 36(8):884&#x2013;888. https://doi.org/10.1093/rheumatology/36.8.884</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/36.8.884</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong Z, van der Heijde D, McKenna SP, Whalley D (1997) The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 36(8):878&#x2013;883. https://doi.org/10.1093/rheumatology/36.8.878</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/36.8.878</ArticleId><ArticleId IdType="pubmed">9291857</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63(2):162&#x2013;169. https://doi.org/10.1136/ard.2003.006296</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2003.006296</ArticleId><ArticleId IdType="pubmed">14722205</ArticleId><ArticleId IdType="pmc">1754880</ArticleId></ArticleIdList></Reference><Reference><Citation>Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde D, Chamberlain MA (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62(1):20&#x2013;26. https://doi.org/10.1136/ard.62.1.20</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.1.20</ArticleId><ArticleId IdType="pubmed">12480664</ArticleId><ArticleId IdType="pmc">1754293</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan AM, McKenna SP, Doward LC, Conaghan PG, Emery P, Tennant A (2008) Development and validation of a needs-based quality of life instrument for osteoarthritis. Arthritis Rheum 59(6):841&#x2013;848. https://doi.org/10.1002/art.23714</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23714</ArticleId><ArticleId IdType="pubmed">18512719</ArticleId></ArticleIdList></Reference><Reference><Citation>Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use, 2nd edn. Oxford University Press, New York</Citation></Reference><Reference><Citation>Weiner EA, Stewart BJ (1984) Assessing individuals Little Brown, Boston</Citation></Reference><Reference><Citation>Hunt SM, Alonso J, Bucquet D, Niero M, Wiklund I, McKenna S (1991) Cross-cultural adaptation of health measures. Eur Group Health Manag Qual Life Assess Health Policy 19(1):33&#x2013;44. https://doi.org/10.1016/0168-8510(91)90072-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8510(91)90072-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SM, McKenna SP, McEwen J, Williams J, Papp E (1981) The Nottingham Health profile: subjective health status and medical consultations. Soc Sci Med A 15(3 Pt 1):221&#x2013;229. https://doi.org/10.1016/0271-7123(81)90005-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0271-7123(81)90005-5</ArticleId><ArticleId IdType="pubmed">6973203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahieu M, Yount S, Ramsey-Goldman R (2016) Patient-reported outcomes in systemic lupus erythematosus. Rheum Dis Clin North Am 42:253&#x2013;263. https://doi.org/10.1016/j.rdc.2016.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2016.01.001</ArticleId><ArticleId IdType="pubmed">27133488</ArticleId><ArticleId IdType="pmc">4853651</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesinska M, Saletra A (2018) Quality of life in systemic lupus erythematosus and its measurement. Reumatologia. 56:45&#x2013;54. https://doi.org/10.5114/reum.2018.74750</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2018.74750</ArticleId><ArticleId IdType="pubmed">29686443</ArticleId><ArticleId IdType="pmc">5911658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dua AB, Touma Z, Toloza S, Jolly M (2013) Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr Rheumatol Rep 15(12):380. https://doi.org/10.1007/s11926-013-0380-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-013-0380-9</ArticleId><ArticleId IdType="pubmed">24178589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>